Thirty four healthcare deals crossed the wire the week of July 13, 2026. Four of the five that matter paid cash for something that already works: an operating rare-disease pharmacy, an FDA-approved drug, a Phase 3 asset with Breakthrough.
Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
Merck’s $9.2 billion acquisition of Cidara brings CD388, a Phase 3 long-acting influenza antiviral, into its pipeline while adding the Cloudbreak® drug-Fc conjugate platform for future oncology and infectious-disease programs.
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
Healthcare deal spotlight September 1 to 7, 2025